-
Published 6/3/2026
Berk JL, Carroll KJ, Mejia Baranda J, Pilebro B, Samuelsson K, Eldhagen P, Wixner J. Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experience. Amyloid. 2026 Jun 03; 1-7. PMID: 42233236.
-
Published 5/1/2026
Ambardekar AV, Sarswat N, Wright R, Berk J, Davis MK, Garcia-Pavia P, Gillmore JD, Grodin JL, Mitchell JD, Mooney D, Nativi-Nicolau J, Poulsen SH, Ruberg FL, Chen C, Ji A, Siddhanti S, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Maurer MS, Cheng RK. Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876. PMID: 42128580.
-
Published 4/15/2026
Sanchorawala V, Greatsinger A, Staron A, Berk JL, Mendelson LM, Joshi T, J Burke N, Tabatabaeepour N, Smith J, Signorovitch J. Disease burden of ATTR amyloidosis based on the SF-36® health survey. Cardiooncology. 2026 Apr 15; 12(1). PMID: 41987333.
-
Published 1/1/2026
Alexander KM, Davis MK, Akinboboye O, Berk J, Bhatt K, Cappelli F, Cuddy SAM, Fontana M, Garcia-Pavia P, Gillmore JD, Griffin JM, Grodin JL, Judge DP, Khouri MG, Lam K, Masri A, Maurer MS, Obici L, Ruberg FL, Sarswat N, Shah K, Soman P, Stern L, Wright R, Xiong K, Cao X, Lystig T, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Solomon SD, Grogan M. Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. JAMA Cardiol. 2026 Jan 01; 11(1):57-67. PMID: 41205147.
-
Published 10/28/2025
Wixner J, Conceição I, Berk JL, Adams D, Polydefkis MJ, Attarian S, Gillmore JD, Dyck PJB, Chen J, Kwoh TJ, Nåtman J, Zhou W, Cruz MW. Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2026 Mar; 33(1):85-89. PMID: 41147681.